These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34659816)

  • 1. Clinicopathologic features and prognostic value of epidermal growth factor receptor mutation in patients with pT1a and pT1b invasive lung adenocarcinoma after surgical resection.
    Chen S; Yang S; Zhang Y; Xiang J; Zhang Y; Hu H; Sun Y; Fu F; Deng C; Wang S; Li Q; Gu Y; Li Y; Shen X; Ye T
    J Thorac Dis; 2021 Sep; 13(9):5496-5507. PubMed ID: 34659816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
    Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma.
    Motono N; Funasaki A; Sekimura A; Usuda K; Uramoto H
    Med Oncol; 2018 Jan; 35(3):22. PubMed ID: 29387978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
    Yoshida T; Ishii G; Goto K; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Nagai K; Ohe Y; Ochiai A
    J Cancer Res Clin Oncol; 2013 Oct; 139(10):1691-700. PubMed ID: 23974272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implication of tumor spread through air spaces in patients with pathologic N0 lung adenocarcinoma.
    Chen S; Ye T; Yang S; Zhao Y; Zhang Y; Huang Q; Wu H; Hu H; Sun Y; Zhang Y; Xiang J; Wang S; Gu Y; Jin Y; Li Y; Chen H
    Lung Cancer; 2022 Feb; 164():33-38. PubMed ID: 34974223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
    Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
    Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.
    Saruwatari K; Ikemura S; Sekihara K; Kuwata T; Fujii S; Umemura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Ochiai A; Kohrogi H; Tsuboi M; Goto K; Ishii G
    Lung Cancer; 2016 Jan; 91():7-14. PubMed ID: 26711928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma.
    Xu Y; Zhu C; Qian W; Zheng M
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):181-186. PubMed ID: 27738759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma.
    Zhang Y; Li J; Wang R; Li Y; Pan Y; Cai D; Hu H; Li H; Ye T; Luo X; Zhang Y; Li B; Shen L; Sun Y; Chen H
    Sci Rep; 2014 Nov; 4():7163. PubMed ID: 25418354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients.
    Sun Y; Yu X; Shi X; Hong W; Zhao J; Shi L
    World J Surg Oncol; 2014 May; 12():148. PubMed ID: 24885205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
    Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
    Matsumura Y; Suzuki H; Ohira T; Shiono S; Abe J; Sagawa M; Sakurada A; Katahira M; Machida Y; Takahashi S; Okada Y
    Lung Cancer; 2017 Dec; 114():23-30. PubMed ID: 29173761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of a consecutive cohort validating an epidermal growth factor receptor mutation as an independent risk factor for postoperative recurrence in lung adenocarcinoma.
    Matsumura Y; Hayasaka K; Ohira T; Shiono S; Abe J; Notsuda H; Sakurada A; Suzuki H; Okada Y
    Interdiscip Cardiovasc Thorac Surg; 2023 Nov; 37(5):. PubMed ID: 37930012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Value of Non-Predominant Micropapillary Pattern in a Large Cohort of Resected Invasive Lung Adenocarcinoma Measuring ≤3 cm.
    Zhang H; Huang W; Liu C; Giaccone G; Zhao X; Sun X; Li J; Cheng R; Huang Q; Mo H; Zhang Z; Zhang B; Wang C
    Front Oncol; 2021; 11():657506. PubMed ID: 34026636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
    Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
    J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System.
    Kudo Y; Shimada Y; Saji H; Kato Y; Yoshida K; Matsubayashi J; Nagase S; Kakihana M; Kajiwara N; Ohira T; Nagao T; Ikeda N
    Clin Lung Cancer; 2015 Nov; 16(6):e213-21. PubMed ID: 25986624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
    Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
    J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H
    J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.